Medical Pharmacology: Chapter: CHF — Chapter 10 -- Module: CHF-02

Chapter: CHF — Chapter 10 — Module: CHF-02 — RAAS Blockade in Heart Failure
Tier: T3

1. A 66-year-old man with HFrEF (heart failure with reduced ejection fraction, LVEF 31%) is started on lisinopril. His cardiologist explains that the drug works through two simultaneous mechanisms. Which of the following correctly identifies both?

A) Lisinopril blocks the AT1 receptor (angiotensin type 1 receptor), reducing angiotensin II signaling, and simultaneously inhibits neprilysin, raising circulating natriuretic peptide levels and amplifying natriuresis and vasodilation
B) Lisinopril suppresses renin secretion from the juxtaglomerular apparatus and simultaneously blocks aldosterone synthesis in the adrenal cortex through direct mineralocorticoid receptor antagonism, reducing sodium retention and maladaptive cardiac remodeling
C) Lisinopril inhibits angiotensin-converting enzyme, blocking conversion of angiotensin I to angiotensin II and simultaneously impairing degradation of bradykinin — a vasodilatory kinin — by the same enzyme; reduced angiotensin II decreases vasoconstriction and aldosterone release, while elevated bradykinin amplifies vasodilation and natriuresis
D) Lisinopril activates the angiotensin-(1-7)/Mas receptor pathway by diverting angiotensin I toward ACE2-mediated cleavage, and simultaneously suppresses aldosterone synthesis by inhibiting the cytochrome P450 enzyme CYP11B2 in the adrenal zona glomerulosa
E) Lisinopril blocks the AT1 receptor and simultaneously stimulates the AT2 receptor (angiotensin type 2 receptor); AT2 receptor activation mediates vasodilation and anti-fibrotic signaling, complementing the reduction in AT1-mediated vasoconstriction to produce the full hemodynamic benefit of RAAS blockade in HFrEF

ANSWER: C

Rationale:

Option C is correct. Angiotensin-converting enzyme (ACE) is a dipeptidyl carboxypeptidase with two distinct substrate functions: it cleaves angiotensin I to generate angiotensin II, and it degrades bradykinin into inactive fragments. ACE inhibitors inhibit both functions simultaneously — reducing angiotensin II production (which decreases vasoconstriction, aldosterone release, sympathetic activation, and maladaptive cardiac remodeling) and impairing bradykinin inactivation (which raises bradykinin levels, amplifying vasodilation, natriuresis, and endothelial nitric oxide release). Both effects arise from inhibition of the same enzyme acting on two different substrates.

Option A: Option A is incorrect; lisinopril does not block the AT1 receptor — that is the mechanism of ARBs (angiotensin receptor blockers); lisinopril also does not inhibit neprilysin — that is the mechanism of sacubitril in the sacubitril/valsartan combination.
Option B: Option B is incorrect; ACE inhibitors cause reactive hyperreninemia — reduced angiotensin II negative feedback increases renin secretion rather than suppressing it; ACEi have no direct mineralocorticoid receptor antagonist activity.
Option D: Option D is incorrect; while ACE inhibition does allow some diversion of angiotensin I toward ACE2-mediated angiotensin-(1-7), this is not the primary recognized mechanism of ACEi benefit; lisinopril does not inhibit CYP11B2 or directly block adrenal aldosterone synthesis.
Option E: Option E is incorrect; lisinopril does not block the AT1 receptor — it acts at the converting enzyme upstream of the receptor; the description of combined AT1 blockade with AT2 stimulation is the proposed mechanism of benefit from AT1-selective receptor blockers (ARBs), not ACEi.

2. A 61-year-old woman with HFrEF develops a persistent dry cough 3 weeks after starting ramipril. She has no history of asthma. Which of the following best describes the mechanism of this adverse effect and the correct management?

A) The cough results from angiotensin II accumulation at AT2 receptors in bronchial smooth muscle, producing bronchoconstriction; it is dose-dependent and managed by reducing the ramipril dose by half; if cough persists, switching to a hydrophilic ACEi such as lisinopril is appropriate because lipophilic agents such as ramipril penetrate lung tissue more extensively
B) The cough results from elevated angiotensin I levels accumulating proximal to the ACE block, directly stimulating TRP (transient receptor potential) channels on bronchial C-fiber afferents; it is a class effect but is dose-dependent and typically resolves with dose reduction to the minimum effective dose
C) The cough results from reactive hyperreninemia — the rise in renin caused by loss of angiotensin II negative feedback activates the kallikrein-kinin system, generating excess bradykinin that accumulates in the airways; because the mechanism is renin-driven, adding a direct renin inhibitor such as aliskiren resolves the cough while maintaining the therapeutic benefit of ACE inhibition
D) The cough results from reduced prostaglandin E2 synthesis in the airway epithelium as a consequence of bradykinin-mediated arachidonic acid shunting; it is specific to agents with high pulmonary ACE affinity and does not occur with low-affinity ACEi such as enalapril; switching to enalapril resolves the cough in the majority of patients
E) The cough results from bradykinin accumulation in the bronchial mucosa — ACE inhibition impairs bradykinin degradation, sensitizing bronchial C-fiber afferents; it is a class effect of all ACEi, is not dose-dependent, and resolves only upon drug discontinuation; the correct management is to switch to an ARB (angiotensin receptor blocker) or to sacubitril/valsartan if the patient has no history of ACEi-associated angioedema

ANSWER: E

Rationale:

Option E is correct. ACEi-induced cough is caused by bradykinin accumulation: angiotensin-converting enzyme degrades bradykinin in the pulmonary vasculature and bronchial mucosa, and its inhibition allows bradykinin to accumulate and stimulate bradykinin B2 receptors on bronchial sensory C-fiber afferents, lowering the cough reflex threshold. This is a class effect occurring in approximately 15–20% of Western patients — it occurs with all ACEi regardless of lipophilicity or pulmonary ACE affinity, is not dose-dependent, and does not improve with dose reduction. The cough resolves only upon drug discontinuation. Management requires switching drug class: an ARB (which does not inhibit ACE and therefore does not raise bradykinin) reliably resolves the cough, as does direct transition to sacubitril/valsartan in ARNI-eligible patients without angioedema history.

Option A: Option A is incorrect; ACEi cough is caused by bradykinin accumulation — not angiotensin II at AT2 receptors; it is not dose-dependent and cannot be managed by dose reduction; it is not specific to lipophilic ACEi such as ramipril — it is a class effect of all ACEi.
Option B: Option B is incorrect; angiotensin I accumulation proximal to the ACE block is not the mechanism of ACEi cough; bradykinin accumulation from impaired ACE-mediated degradation is; the cough is not dose-dependent and does not resolve with dose reduction.
Option C: Option C is incorrect; while reactive hyperreninemia does occur with ACEi (from reduced Ang II negative feedback), and renin does activate the kallikrein-kinin system, this is not the primary mechanism of bronchial bradykinin accumulation in ACEi cough; aliskiren (a direct renin inhibitor) does not reliably resolve ACEi cough, and combining ACEi with aliskiren carries its own adverse renal and hemodynamic risks.
Option D: Option D is incorrect; ACEi cough is not specific to agents with high pulmonary ACE affinity; enalapril produces ACEi cough at comparable incidence to ramipril; switching between ACEi does not reliably resolve the cough, as it is a class effect.

3. A resident asks why sacubitril must be combined with valsartan in sacubitril/valsartan (Entresto) rather than used as a standalone neprilysin inhibitor in HFrEF. Which of the following correctly explains the pharmacodynamic necessity of the combination?

A) Sacubitril alone causes severe hyperkalemia because neprilysin degrades aldosterone in the adrenal cortex; without neprilysin, aldosterone accumulates, driving collecting duct potassium retention to dangerous levels; valsartan blocks AT1-mediated aldosterone stimulation to counteract this effect
B) Neprilysin degrades multiple vasoactive substrates including natriuretic peptides and angiotensin II; when neprilysin is inhibited by sacubitril, angiotensin II degradation is also impaired and Ang II levels rise; unopposed elevated Ang II would drive vasoconstriction, aldosterone release, and maladaptive cardiac remodeling — counteracting the benefit of natriuretic peptide accumulation; valsartan blocks the AT1 receptor to neutralize this rise in Ang II, ensuring the net pharmacodynamic result of neprilysin inhibition is beneficial
C) Sacubitril's active metabolite LBQ657 is rapidly cleared by renal tubular secretion; valsartan competitively inhibits the organic anion transporter responsible for LBQ657 elimination, extending sacubitril's pharmacodynamic half-life sufficiently to maintain continuous neprilysin inhibition throughout the twice-daily dosing interval
D) Sacubitril alone produces excessive accumulation of ANP (atrial natriuretic peptide) and BNP (B-type natriuretic peptide) that overwhelms NPR-A receptor (natriuretic peptide receptor A) capacity; paradoxical receptor downregulation follows, eliminating the natriuretic peptide signaling benefit; valsartan prevents NPR-A downregulation by blocking AT1-mediated receptor internalization
E) Sacubitril alone would produce dangerous sinus bradycardia through natriuretic peptide-mediated suppression of sinoatrial node automaticity at therapeutic plasma concentrations; valsartan attenuates natriuretic peptide chronotropic effects by competitively blocking NPR-A at cardiac pacemaker cells, reducing heart rate suppression to a clinically acceptable level

ANSWER: B

Rationale:

Option B is correct. Neprilysin is a broad-substrate peptidase — while its therapeutically targeted substrates are the natriuretic peptides (ANP, BNP, CNP), it also degrades angiotensin II. When sacubitril inhibits neprilysin, angiotensin II degradation is simultaneously impaired, causing Ang II levels to rise. Because Ang II is the primary driver of maladaptive neurohormonal activation in HFrEF — producing vasoconstriction, aldosterone secretion, sympathetic potentiation, and pathological cardiac fibrosis — a standalone neprilysin inhibitor would produce a pharmacodynamically self-defeating result: raising beneficial counter-regulatory natriuretic peptides while simultaneously raising the maladaptive driver of HFrEF progression. The valsartan component blocks the AT1 receptor, preventing elevated Ang II from exerting its harmful effects. This rational pairing — neprilysin inhibition for natriuretic peptide amplification, AT1 blockade for Ang II neutralization — is the mechanistic foundation of the sacubitril/valsartan design.

Option A: Option A is incorrect; neprilysin does not degrade aldosterone in the adrenal cortex as a clinically meaningful pathway; hyperkalemia is not the primary risk from standalone neprilysin inhibition; the rationale for valsartan is Ang II accumulation at the systemic level, not adrenal aldosterone.
Option C: Option C is incorrect; the necessity of combining sacubitril with valsartan is pharmacodynamic, not pharmacokinetic; LBQ657 renal clearance inhibition by valsartan is not an established pharmacokinetic mechanism, and the combination would not be required on pharmacokinetic grounds alone.
Option D: Option D is incorrect; natriuretic peptide receptor downregulation from NPR-A overload is not an established mechanism of clinical significance with sacubitril therapy; AT1-mediated NPR-A internalization blocked by valsartan is pharmacologically fabricated.
Option E: Option E is incorrect; natriuretic peptides do not suppress sinoatrial node automaticity to a clinically significant degree at therapeutic concentrations; bradycardia is not a recognized adverse effect of neprilysin inhibition, and valsartan is not included to attenuate natriuretic peptide chronotropic effects.

4. A 69-year-old man with HFrEF on sacubitril/valsartan presents with worsening dyspnea and 4 kg weight gain over 2 weeks. His BNP (B-type natriuretic peptide) is 205 pg/mL. His intern considers this only mildly elevated and attributes the symptoms to deconditioning. The attending disagrees. Which of the following best explains the attending's concern?

A) A BNP of 205 pg/mL in any HFrEF patient is above the diagnostic threshold for acute decompensation and mandates immediate hospitalization for intravenous diuresis; the intern's interpretation is incorrect because BNP thresholds apply uniformly regardless of the patient's medication regimen
B) The attending is concerned because sacubitril/valsartan effectively suppresses BNP synthesis by reducing ventricular wall stress; a BNP of 205 pg/mL therefore represents a relatively high value for an optimally treated patient and actually confirms significant hemodynamic decompensation — not a mildly elevated result
C) The attending is concerned because the valsartan component of sacubitril/valsartan competitively inhibits the BNP immunoassay antibody, producing falsely elevated BNP readings; the true BNP in this patient is therefore lower than 205 pg/mL, and NT-proBNP (N-terminal pro-BNP) should be ordered because it uses a different assay antibody unaffected by valsartan
D) The attending is concerned because sacubitril inhibits neprilysin — the primary enzyme responsible for degrading BNP in the circulation; BNP accumulates artifactually in patients on sacubitril/valsartan, making it an unreliable marker of true ventricular filling pressure; the correct biomarker is NT-proBNP, which is not a neprilysin substrate and remains accurate; the clinical picture — 4 kg weight gain and worsening dyspnea — cannot be dismissed on the basis of a pharmacologically uninterpretable BNP value
E) The attending is concerned because BNP of 205 pg/mL is below the lower limit of assay detection in patients on sacubitril/valsartan due to complete neprilysin-mediated BNP suppression; values below 300 pg/mL in patients on ARNI therapy are considered equivalent to an undetectable BNP and indicate complete hemodynamic normalization, making the intern's assessment of only mild elevation an understatement of how well-controlled this patient actually is

ANSWER: D

Rationale:

Option D is correct. BNP is a substrate for neprilysin — the enzyme inhibited by the sacubitril component of sacubitril/valsartan. When neprilysin is inhibited, BNP degradation in the circulation is impaired, causing BNP to accumulate independent of true changes in ventricular wall stress or filling pressures. This renders BNP uninterpretable as a biomarker of HF severity in patients on sacubitril/valsartan. The intern's error is accepting a BNP of 205 pg/mL as reassuringly low when it may reflect artifactual accumulation from impaired degradation rather than genuine neurohormonal control. NT-proBNP (N-terminal pro-BNP) is the inactive N-terminal cleavage fragment of the BNP prohormone; it is not a neprilysin substrate and is unaffected by sacubitril, making it the reliable biomarker for assessing congestion in this population. Four kilograms of weight gain and worsening dyspnea over 2 weeks are clinically significant warning signs that cannot be dismissed on the basis of an invalid biomarker result.

Option A: Option A is incorrect; BNP thresholds for decompensation do not apply uniformly regardless of medication regimen; in patients on sacubitril/valsartan, BNP is pharmacologically uninterpretable and standard BNP cutoffs should not be used to guide clinical decisions.
Option B: Option B is incorrect; while sacubitril/valsartan does reduce neurohormonal activation over time, the primary reason BNP is unreliable on this regimen is impaired enzymatic degradation from neprilysin inhibition, not genuine synthesis suppression; the attending's concern is the inverse of this option — the attending worries the BNP underestimates decompensation, not confirms it.
Option C: Option C is incorrect; there is no structural homology between valsartan and BNP that causes immunoassay antibody competitive inhibition; BNP immunoassays are not subject to interference by ARBs; BNP unreliability on ARNI therapy is caused by the sacubitril (neprilysin inhibitor) component, not the valsartan component.
Option E: Option E is incorrect; there is no established threshold below which BNP values on ARNI therapy indicate complete hemodynamic normalization; no validated ARNI-specific BNP interpretation algorithm exists; the described 300 pg/mL equivalence framework is pharmacologically fabricated.

5. A hospitalist is managing three HFrEF patients requiring RAAS agent transitions. Patient 1 is switching from enalapril to sacubitril/valsartan. Patient 2 is switching from candesartan to sacubitril/valsartan. Patient 3 developed angioedema on sacubitril/valsartan and is being switched to ramipril. Which of the following correctly describes the washout requirement for all three transitions?

A) Patient 1: 36-hour washout after last enalapril dose before starting sacubitril/valsartan — concurrent ACE inhibition and neprilysin inhibition both independently impair bradykinin degradation, producing additive accumulation and unacceptable angioedema risk. Patient 2: no washout required — candesartan does not inhibit ACE or neprilysin and does not raise bradykinin; discontinue candesartan on the day sacubitril/valsartan is started. Patient 3: 36-hour washout after stopping sacubitril/valsartan before starting ramipril — residual neprilysin inhibition from sacubitril combined with new ACEi-mediated bradykinin accumulation creates the same additive risk in reverse
B) All three transitions require a 36-hour washout; the interval is universally mandated before any change in RAAS-modifying therapy to prevent rebound neurohormonal activation, and the 2022 AHA/ACC/HFSA guidelines endorse this uniform interval regardless of direction or agent class
C) Patient 1: 36-hour washout required. Patient 2: 72-hour washout required because candesartan has a prolonged AT1 receptor dissociation half-life; residual AT1 blockade combined with the valsartan component of sacubitril/valsartan risks additive hypotension for up to 3 days. Patient 3: no washout required because LBQ657 (the active sacubitril metabolite) is fully cleared renally within 12 hours of the last dose
D) Patient 1: taper enalapril over 2 weeks before initiating sacubitril/valsartan; abrupt ACEi discontinuation in HFrEF risks rebound neurohormonal activation and hemodynamic deterioration. Patient 2: 36-hour washout required. Patient 3: no washout required
E) Patient 1: no washout required because enalapril has a plasma half-life under 2 hours and is fully cleared within 6 hours of the last dose; same-day initiation of sacubitril/valsartan is safe. Patient 2: no washout required. Patient 3: 36-hour washout required before starting ramipril

ANSWER: A

Rationale:

Option A is correct. The three transition protocols are mechanistically distinct. For Patient 1 (ACEi → ARNI): a mandatory 36-hour washout is required because ACE inhibitors impair bradykinin degradation via ACE, and sacubitril impairs bradykinin degradation via neprilysin — two independent enzymatic pathways; simultaneous inhibition of both causes additive bradykinin accumulation that risks potentially fatal laryngeal angioedema. For Patient 2 (ARB → ARNI): no washout is required because candesartan blocks the AT1 receptor without inhibiting ACE or neprilysin; bradykinin degradation proceeds normally throughout ARB therapy; there is no bradykinin accumulation risk to carry over; discontinue candesartan on the day sacubitril/valsartan is started. For Patient 3 (ARNI → ACEi): a 36-hour washout after stopping sacubitril/valsartan is required before initiating ramipril — the same mechanistic reason applies in reverse; residual neprilysin inhibition from sacubitril combined with new ACEi-mediated bradykinin elevation from ramipril would produce the same dangerous additive accumulation.

Option B: Option B is incorrect; a universal 36-hour washout for all RAAS transitions is not guideline-endorsed; the ARB-to-ARNI transition requires no washout, and applying one unnecessarily delays therapy without pharmacological justification.
Option C: Option C is incorrect; candesartan does not require a 72-hour washout due to AT1 receptor dissociation kinetics; ARB-to-ARNI transition requires no washout; Patient 3 does require a 36-hour washout — LBQ657 is not fully cleared within 12 hours in a clinically meaningful pharmacodynamic sense, and the washout requirement is based on pharmacodynamic recovery of neprilysin activity, not simple plasma clearance.
Option D: Option D is incorrect; no gradual taper of enalapril is required before transitioning to sacubitril/valsartan; the correct protocol is abrupt cessation followed by the 36-hour washout; candesartan requires no washout, not a 36-hour washout.
Option E: Option E is incorrect; enalaprilat (the active diacid metabolite of enalapril) does not have a plasma half-life under 2 hours — its effective pharmacodynamic half-life with tissue ACE inhibition is substantially longer than plasma kinetics suggest; the 36-hour washout is based on pharmacodynamic ACE activity recovery, not plasma enalapril clearance; same-day initiation after stopping an ACEi is not safe.

6. Which of the following most accurately describes the design, active comparator, primary outcome, and key design feature of PARADIGM-HF?

A) PARADIGM-HF randomized 8,442 patients with HFrEF to sacubitril/valsartan versus placebo added to background enalapril therapy; sacubitril/valsartan reduced the primary composite of cardiovascular death or HF hospitalization by 20%; no run-in period was employed, reflecting the real-world unselected HFrEF population
B) PARADIGM-HF randomized 3,164 patients with HFrEF to sacubitril/valsartan versus enalapril; the primary endpoint of all-cause mortality was reduced by 20% (HR 0.80); the trial was stopped early for overwhelming efficacy after a mandatory run-in period pre-selected patients tolerant of both agents
C) PARADIGM-HF randomized 8,442 patients with HFrEF (LVEF ≤40%, NYHA class II–IV) to sacubitril/valsartan versus enalapril; sacubitril/valsartan reduced the primary composite of cardiovascular death or HF hospitalization by 20% (HR 0.80; p<0.001), reduced all-cause mortality by 16%, and reduced sudden cardiac death by 20%; the trial was stopped early for overwhelming efficacy, and a mandatory sequential run-in period ensured enrolled patients had demonstrated tolerability of both agents before randomization
D) PARADIGM-HF compared sacubitril/valsartan to valsartan alone to isolate the contribution of the neprilysin inhibitor component; sacubitril/valsartan reduced the primary composite by 20%, demonstrating that sacubitril provides incremental mortality benefit over AT1 blockade alone; no run-in period was used
E) PARADIGM-HF demonstrated that sacubitril/valsartan reduced HF hospitalization rates but did not achieve statistical significance for cardiovascular mortality as an independent secondary endpoint; the FDA approved sacubitril/valsartan based on the composite endpoint alone, with a labeling statement that the mortality reduction was driven primarily by the hospitalization component

ANSWER: C

Rationale:

Option C is correct. PARADIGM-HF enrolled 8,442 patients with chronic HFrEF (LVEF ≤40%, NYHA class II–IV, elevated natriuretic peptides) and randomized them to sacubitril/valsartan 97/103 mg twice daily or enalapril 10 mg twice daily. The primary composite endpoint — cardiovascular death or first HF hospitalization — was reduced by 20% (HR 0.80; 95% CI 0.73–0.87; p<0.001). Key secondary endpoint reductions were all statistically significant: all-cause mortality 16%, cardiovascular mortality 20%, HF hospitalization 21%, and sudden cardiac death 20%. The trial was stopped early by the data safety monitoring board for overwhelming efficacy. A critical design feature was the mandatory sequential run-in period: all patients first received enalapril alone, then sacubitril/valsartan alone, before randomization — selecting a population that had demonstrated tolerability of both agents and likely underestimating absolute benefit in unselected patients.

Option A: Option A is incorrect; PARADIGM-HF compared sacubitril/valsartan directly to enalapril as the active comparator, not to placebo on background enalapril; combining ARNI with ACEi is contraindicated; a run-in period was a key design feature of the trial.
Option B: Option B is incorrect on two counts: the trial enrolled 8,442 patients, not 3,164; and the primary endpoint was the composite of cardiovascular death or HF hospitalization, not all-cause mortality alone — all-cause mortality was a secondary endpoint reduced by 16%, not 20%.
Option D: Option D is incorrect; PARADIGM-HF compared sacubitril/valsartan to enalapril, not to valsartan alone; the design tested ARNI against standard-of-care ACEi, not against the ARB component; a run-in period was employed.
Option E: Option E is incorrect; PARADIGM-HF demonstrated statistically significant reductions in cardiovascular mortality as an independent endpoint; there is no FDA labeling statement attributing the mortality benefit entirely to the hospitalization component; this characterization is factually incorrect.

7. A medical student argues that combining an ACEi with an ARB provides superior RAAS blockade and should improve outcomes in HFrEF. Which of the following best explains why current guidelines advise against this combination?

A) Dual ACEi plus ARB therapy is endorsed as a Class IIa recommendation in the 2022 AHA/ACC/HFSA guidelines for HFrEF patients who remain symptomatic (NYHA class III–IV) despite single-agent RAAS therapy optimized to target dose; CHARM-Added demonstrated a significant all-cause mortality reduction with candesartan added to background ACEi, supporting the guideline recommendation
B) Dual ACEi plus ARB therapy is inadvisable solely because of hyperkalemia risk; the combination is acceptable in patients with well-controlled baseline potassium (K⁺ <4.5 mEq/L) and eGFR above 60 mL/min/1.73m², and carries a Class IIb (weak positive) recommendation in this carefully selected subpopulation under monthly electrolyte monitoring
C) Dual ACEi plus ARB therapy is contraindicated because ARBs competitively displace ACEi molecules from the ACE active site, reducing ACE inhibition below the therapeutic threshold needed for meaningful Ang II suppression; the net result is inadequate RAAS blockade and pharmacodynamic self-antagonism
D) Dual ACEi plus ARB therapy is not contraindicated — it is simply deprioritized because sacubitril/valsartan has superseded it; in patients who cannot access sacubitril/valsartan, ACEi plus ARB remains a guideline-acceptable RAAS strategy per the 2022 AHA/ACC/HFSA guidelines
E) Dual ACEi plus ARB therapy is not recommended; the ONTARGET trial demonstrated that combining ramipril with telmisartan significantly increased rates of hypotension, acute kidney injury, and dialysis initiation without reducing the primary cardiovascular endpoint compared to either agent alone; current guidelines advise against this combination, and it is specifically contraindicated when an MRA (mineralocorticoid receptor antagonist) is already present in the regimen

ANSWER: E

Rationale:

Option E is correct. The ONTARGET trial enrolled high-cardiovascular-risk patients and demonstrated that combining ramipril and telmisartan significantly increased rates of hypotension, acute kidney injury, doubling of serum creatinine, and initiation of dialysis compared to either agent alone — without any reduction in the primary composite of cardiovascular death, myocardial infarction, stroke, or HF hospitalization. This adverse renal and hemodynamic signal without benefit shifted the risk-benefit analysis decisively against routine dual RAAS blockade. The 2022 AHA/ACC/HFSA guidelines do not recommend ACEi plus ARB combination therapy in HFrEF. The combination is additionally and specifically contraindicated when an MRA (spironolactone or eplerenone) is already in the regimen — the triple combination produces unacceptable rates of hyperkalemia and renal deterioration. When more complete RAAS blockade is desired in an eligible patient, the correct strategy is to transition to sacubitril/valsartan, not to add an ARB to an ACEi.

Option A: Option A is incorrect; the 2022 AHA/ACC/HFSA guidelines do not give ACEi plus ARB dual therapy a Class IIa recommendation; CHARM-Added demonstrated a reduction in HF hospitalization but did not produce a statistically significant reduction in all-cause mortality in isolation; the ONTARGET renal harm data preclude a positive guideline recommendation for this combination.
Option B: Option B is incorrect; the contraindication to ACEi plus ARB is not limited to hyperkalemia risk — ONTARGET demonstrated renal harm as the predominant adverse signal even in patients without significant baseline hyperkalemia; the combination carries no positive guideline recommendation in any selected subpopulation.
Option C: Option C is incorrect; ARBs do not bind to ACE or competitively displace ACEi from the ACE active site; ARBs act at the AT1 receptor, which is entirely downstream and distinct from the converting enzyme; there is no pharmacodynamic antagonism between ACEi and ARB at the enzyme level.
Option D: Option D is incorrect; ACEi plus ARB is not merely deprioritized in favor of sacubitril/valsartan — it is actively not recommended due to demonstrated renal harm; ACEi alone or ARB alone (not in combination) is the appropriate alternative when ARNI is unavailable; this distinction is clinically important.

8. A 65-year-old man with HFrEF on enalapril presents with sudden-onset lip and tongue swelling without urticaria. The reaction resolves with supportive care. Which of the following correctly identifies the mechanism and appropriate future RAAS therapy?

A) This is an IgE-mediated type I hypersensitivity reaction; cross-reactivity among ACEi is low, so switching to a structurally dissimilar ACEi is safe; sacubitril/valsartan is contraindicated because its ARB component shares the sulfonamide moiety that triggered the IgE response
B) This is ACEi-induced angioedema caused by bradykinin accumulation from impaired ACE-mediated bradykinin degradation; the absence of urticaria is characteristic; this is an absolute contraindication to rechallenge with any ACEi (class effect) and to sacubitril/valsartan (which raises bradykinin independently via neprilysin inhibition); an ARB is the appropriate RAAS-blocking alternative because ARBs do not inhibit ACE or neprilysin and do not raise bradykinin
C) This is ACEi-induced angioedema caused by bradykinin accumulation; because the reaction occurred after 6 months of therapy it represents a delayed-onset immune sensitization; desensitization with a graduated enalapril rechallenge protocol under allergist supervision is appropriate before committing to permanent drug class change
D) This is ACEi-induced angioedema caused by angiotensin II accumulation at submucosal AT2 receptors; switching to sacubitril/valsartan is appropriate because the valsartan component provides AT2 receptor blockade, preventing the submucosal edema mechanism; ARBs that block only AT1 are insufficient
E) This is ACEi-induced angioedema caused by bradykinin accumulation; switching to a different ACEi is safe because ACEi angioedema is agent-specific — angioedema to enalapril does not predict angioedema to lisinopril or ramipril due to differences in pulmonary ACE affinity and tissue distribution

ANSWER: B

Rationale:

Option B is correct. ACEi-induced angioedema is caused by bradykinin accumulation: ACE inhibition impairs bradykinin degradation in vascular endothelium and submucosal tissues, and elevated bradykinin increases microvascular permeability, producing the characteristic submucosal edema. The absence of urticaria is a distinguishing feature from IgE-mediated allergic angioedema — ACEi angioedema is not immunologically mediated and does not involve histamine release from mast cells. This is an absolute contraindication to: (1) rechallenge with any ACEi — it is a class effect of all agents that inhibit ACE, not specific to enalapril; and (2) sacubitril/valsartan — the sacubitril component inhibits neprilysin, a second independent bradykinin-degrading enzyme, and in a patient sensitized by prior ACEi angioedema, additive bradykinin accumulation from neprilysin inhibition risks potentially fatal laryngeal angioedema. An ARB is the appropriate RAAS-blocking alternative: ARBs block the AT1 receptor without inhibiting ACE or neprilysin, do not raise bradykinin, and are safe in patients with prior ACEi angioedema.

Option A: Option A is incorrect; ACEi angioedema is not IgE-mediated — it is a pharmacodynamic bradykinin-mediated class effect; switching to a different ACEi is not safe; ARBs do not share a sulfonamide moiety with ACEi; sacubitril/valsartan is contraindicated because of the sacubitril (neprilysin inhibitor) component, not because of the ARB component.
Option C: Option C is incorrect; ACEi angioedema is not an immune sensitization phenomenon amenable to desensitization; it is a pharmacodynamic bradykinin-mediated effect that occurs as a class effect at any dose and at any time during therapy; desensitization rechallenge protocols are not appropriate or endorsed for this reaction.
Option D: Option D is incorrect; ACEi angioedema is caused by bradykinin accumulation, not angiotensin II at AT2 receptors; valsartan blocks AT1 receptors, not AT2 receptors; sacubitril/valsartan is contraindicated in patients with prior ACEi angioedema, not recommended as the appropriate switch.
Option E: Option E is incorrect; ACEi angioedema is a class effect — all ACEi raise bradykinin through the same enzymatic inhibition regardless of lipophilicity or pulmonary ACE affinity; switching from enalapril to lisinopril or ramipril carries high risk of recurrent angioedema and is not appropriate management.

9. A 75-year-old woman with HFrEF (LVEF 29%) and stage 3b CKD (eGFR 34 mL/min/1.73m²) is stable and being discharged after an elective visit. Her intern recommends withholding RAAS blockade given the low eGFR. Which of the following best describes the correct approach?

A) RAAS blockade is contraindicated when eGFR is below 45 mL/min/1.73m²; the reduction in intraglomerular pressure accelerates CKD progression regardless of cardioprotective benefit; hydralazine/isosorbide dinitrate is recommended as the RAAS-sparing neurohormonal alternative in this population
B) RAAS blockade should be initiated immediately at this visit with sacubitril/valsartan at the maximum starting dose; the cardioprotective benefit in HFrEF outweighs any renal risk and early high-dose initiation produces the fastest mortality benefit
C) RAAS blockade is safe in stable moderate CKD but sacubitril/valsartan is specifically contraindicated at eGFR below 60 mL/min/1.73m²; an ACEi or ARB should be used until eGFR improves to above this threshold before ARNI transition is considered
D) RAAS blockade is appropriate and guideline-recommended in patients with HFrEF and stable moderate CKD (eGFR approximately 20–60 mL/min/1.73m²); a modest creatinine rise of up to 30% after initiation represents an expected hemodynamic effect — reduced intraglomerular pressure — rather than nephrotoxicity, and is not an indication to withhold therapy; initiate at the lowest available dose, monitor renal function and electrolytes at 1–2 weeks, and hold RAAS blockers temporarily during intercurrent illness causing volume depletion
E) RAAS blockade in HFrEF with CKD requires nephrology consultation and a 3-month specialist-supervised dose-finding period before initiation; the 2022 AHA/ACC/HFSA guidelines mandate nephrology clearance for all HFrEF patients with eGFR below 60 mL/min/1.73m² before commencing RAAS-blocking therapy

ANSWER: D

Rationale:

Option D is correct. RAAS blockade with ACEi or sacubitril/valsartan is appropriate and guideline-indicated in patients with HFrEF and stable moderate CKD (eGFR approximately 20–60 mL/min/1.73m²). Withholding survival-modifying therapy based on moderate CKD alone denies a meaningful mortality benefit. A creatinine rise of up to approximately 30% above baseline after initiation is an expected hemodynamic effect — reduced intraglomerular hydraulic pressure from efferent arteriolar dilation caused by RAAS blockade — rather than intrinsic nephrotoxicity. This degree of creatinine elevation does not predict accelerated CKD progression and is not an indication to discontinue therapy. The correct approach is to initiate at the lowest available dose, monitor potassium and creatinine at 1–2 weeks, and continue unless the creatinine rise is excessive or significant hyperkalemia develops. Sacubitril/valsartan can be used at eGFR as low as approximately 25–30 mL/min/1.73m² with dose adjustment. The sick day rule is equally critical: during volume depletion from any intercurrent illness, RAAS blockers should be temporarily held to prevent AKI.

Option A: Option A is incorrect; there is no eGFR threshold of 45 mL/min/1.73m² that constitutes a contraindication to RAAS blockade in HFrEF; hydralazine/isosorbide dinitrate is not recommended as a universal RAAS-sparing alternative for CKD patients of any racial group — it is specifically indicated as additive therapy in self-identified Black patients with persistent NYHA III–IV symptoms.
Option B: Option B is incorrect; RAAS blockade should be initiated at the lowest available starting dose, not the maximum starting dose; high-dose initiation in CKD significantly increases the risk of hyperkalemia and renal deterioration; slow titration with close monitoring is the correct approach.
Option C: Option C is incorrect; sacubitril/valsartan is not contraindicated at eGFR below 60 mL/min/1.73m²; it can be used at eGFR as low as approximately 25–30 mL/min/1.73m² with dose adjustment; no eGFR threshold of 60 mL/min/1.73m² restricting ARNI eligibility appears in current guidelines.
Option E: Option E is incorrect; the 2022 AHA/ACC/HFSA guidelines do not require nephrology consultation or a supervised dose-finding period before initiating RAAS blockade in CKD stage 3; internists, hospitalists, and cardiologists routinely initiate these agents in moderate CKD without specialist clearance.

10. A 54-year-old man of self-identified Black race with HFrEF (LVEF 23%, NYHA class III) remains symptomatic on optimized sacubitril/valsartan, carvedilol, and spironolactone. His cardiologist proposes adding hydralazine/isosorbide dinitrate (H/ISDN). Which of the following best describes the evidence basis and correct role for H/ISDN in this clinical context?

A) H/ISDN carries a Class I recommendation (2022 AHA/ACC/HFSA) as additive therapy in self-identified Black patients with HFrEF who remain symptomatic (NYHA class III–IV) despite optimized ACEi or ARB and beta-blocker; the A-HeFT trial demonstrated a 43% reduction in all-cause mortality and 33% reduction in HF hospitalization with H/ISDN added to standard background therapy; H/ISDN is additive to RAAS blockade — not a substitute for it — and there is no evidence that H/ISDN replaces the mortality benefit of RAAS-blocking agents in any population
B) H/ISDN is not appropriate in this patient because A-HeFT specifically enrolled patients on ACEi or ARB background therapy; the trial did not enroll patients on sacubitril/valsartan, and guidelines therefore restrict the Class I recommendation to ACEi- or ARB-background patients only; in patients already on ARNI, H/ISDN provides no additional benefit
C) H/ISDN carries a Class IIb recommendation in self-identified Black patients with HFrEF; A-HeFT demonstrated reduction in HF hospitalization only, without statistical significance for all-cause mortality reduction; the weak recommendation reflects the morbidity-only evidence base and should be offered only to patients who have exhausted all other GDMT options
D) H/ISDN is indicated only when RAAS-blocking therapy cannot be used due to adverse effects; in patients already receiving sacubitril/valsartan, H/ISDN provides no additive neurohormonal benefit because ARNI therapy already achieves complete neurohormonal rebalancing through combined natriuretic peptide amplification and AT1 blockade
E) H/ISDN is indicated as first-line neurohormonal therapy in all patients of self-identified Black race with HFrEF regardless of current RAAS blockade status, because this population demonstrates lower plasma renin levels and therefore derives less benefit from RAAS blockade; H/ISDN should replace rather than supplement RAAS-blocking agents in Black patients when direct vasodilatory therapy is available

ANSWER: A

Rationale:

Option A is correct. The 2022 AHA/ACC/HFSA guidelines give H/ISDN a Class I recommendation as additive therapy in patients of self-identified Black race with HFrEF who remain symptomatic (NYHA class III–IV) despite optimized ACEi or ARB therapy plus a beta-blocker. The evidence basis is the A-HeFT trial, which randomized 1,050 self-identified Black patients with NYHA class III–IV HFrEF to fixed-dose H/ISDN (BiDil) or placebo added to standard HF therapy — including ACEi or ARB background in the majority of patients. The trial was stopped early for overwhelming efficacy: H/ISDN reduced all-cause mortality by 43% and HF hospitalization by 33%. The clinical principle is that H/ISDN is additive to RAAS blockade, not a substitute: it does not replace ACEi, ARB, or ARNI therapy, and there is no evidence it provides equivalent mortality reduction to RAAS-blocking agents. This patient, already on sacubitril/valsartan, remains an appropriate candidate for H/ISDN addition based on persistent NYHA III symptoms and self-identified Black race — the more potent RAAS blockade from ARNI does not eliminate the indication for H/ISDN in persistently symptomatic patients.

Option B: Option B is incorrect; while A-HeFT enrolled patients predominantly on ACEi or ARB background, the guideline indication for H/ISDN in self-identified Black patients with persistent NYHA III–IV symptoms is not explicitly restricted to those on ACEi or ARB only; patients on ARNI who remain symptomatic are appropriate candidates for H/ISDN addition based on the underlying evidence and the guideline's symptomatic criterion.
Option C: Option C is incorrect; H/ISDN carries a Class I (strong) recommendation, not Class IIb; A-HeFT demonstrated a statistically significant reduction in all-cause mortality — 43% — which is the primary basis for the strong recommendation; characterizing the evidence as morbidity-only is factually incorrect.
Option D: Option D is incorrect; H/ISDN is not limited to patients intolerant of RAAS-blocking therapy; A-HeFT enrolled patients on background RAAS blockade and demonstrated additive benefit on top of it; the assertion that ARNI eliminates the indication for H/ISDN in persistently symptomatic Black patients has no guideline basis.
Option E: Option E is incorrect; H/ISDN is not recommended as first-line therapy replacing RAAS blockade in Black patients with HFrEF; both RAAS-blocking therapy (Class I) and H/ISDN addition (Class I in symptomatic NYHA III–IV patients) are guideline-recommended in this population, serving complementary rather than competing roles; lower average renin levels in Black patients do not contraindicate RAAS blockade.

11. A 62-year-old woman with HFrEF (LVEF 30%, NYHA class II) has been stable on enalapril 10 mg twice daily, metoprolol succinate 100 mg daily, and eplerenone 25 mg daily for 16 months. Her BP is 120/74 mmHg, creatinine is 1.1 mg/dL (stable), potassium is 4.4 mEq/L, and she has no history of cough or angioedema. She asks if her regimen is optimal. Which of the following is the most appropriate response?

A) Her regimen is fully optimized; enalapril 10 mg twice daily is the dose used in PARADIGM-HF and provides mortality benefit equivalent to sacubitril/valsartan in patients who are already clinically stable; transition to sacubitril/valsartan in a stable NYHA class II patient carries unnecessary risk without additional benefit
B) Enalapril should be uptitrated to 20 mg twice daily before any consideration of ARNI transition; a 6-month period at maximum ACEi dose is required by the 2022 AHA/ACC/HFSA guidelines to document maximum ACEi tolerance before ARNI upgrade eligibility is established
C) She should be transitioned from enalapril to sacubitril/valsartan; the 2022 AHA/ACC/HFSA guidelines give sacubitril/valsartan a Class I recommendation as the preferred RAAS-blocking agent in HFrEF patients with LVEF ≤40% who can tolerate it; she meets all eligibility criteria; the transition requires stopping enalapril, waiting 36 hours, then initiating sacubitril/valsartan 49/51 mg twice daily with uptitration to 97/103 mg twice daily over 2–4 week intervals as tolerated
D) Transition to sacubitril/valsartan should be deferred until she develops NYHA class III symptoms; the Class I guideline recommendation applies to NYHA class III–IV disease, and PARADIGM-HF demonstrated mortality benefit only in the class III–IV subgroup; initiating ARNI in asymptomatic or mildly symptomatic patients is not guideline-supported
E) She should be switched from enalapril to valsartan 160 mg twice daily; the Val-HeFT trial demonstrated that the valsartan component of sacubitril/valsartan is responsible for the primary mortality benefit; standalone high-dose valsartan achieves equivalent outcomes to sacubitril/valsartan at lower cost and without the bradykinin-related angioedema risk of neprilysin inhibition

ANSWER: C

Rationale:

Option C is correct. This patient is an ideal candidate for ARNI transition. The 2022 AHA/ACC/HFSA guidelines give sacubitril/valsartan a Class I recommendation (Level of Evidence A) as the preferred RAAS-blocking agent in symptomatic HFrEF (LVEF ≤40%, NYHA class II–IV) for patients who can tolerate it. She meets all eligibility criteria: hemodynamically stable (SBP >100 mmHg), adequate renal function, normal potassium, and no angioedema or cough history. PARADIGM-HF directly compared sacubitril/valsartan to enalapril 10 mg twice daily — the same dose this patient is receiving — and demonstrated superiority across cardiovascular death, all-cause mortality, HF hospitalization, and sudden cardiac death. Remaining on enalapril when ARNI-eligible leaves a demonstrated mortality benefit unrealized. The mandatory transition protocol is: stop enalapril today, wait 36 hours (to allow ACE activity recovery and prevent additive bradykinin accumulation and angioedema risk from concurrent ACE and neprilysin inhibition), then initiate sacubitril/valsartan 49/51 mg twice daily, titrating to 97/103 mg twice daily every 2–4 weeks as tolerated.

Option A: Option A is incorrect; enalapril and sacubitril/valsartan are not equivalent — PARADIGM-HF directly demonstrated ARNI superiority over enalapril 10 mg twice daily; being stable on enalapril does not mean the patient cannot benefit further from ARNI; the Class I recommendation to transition eligible patients exists precisely because this mortality gap is real and clinically actionable.
Option B: Option B is incorrect; the 2022 AHA/ACC/HFSA guidelines do not require a 6-month period at maximum ACEi dose before ARNI transition; enalapril 10 mg twice daily was the comparator dose in PARADIGM-HF; no mandated prior ACEi duration or dose documentation requirement exists for ARNI eligibility.
Option D: Option D is incorrect; the Class I guideline recommendation for sacubitril/valsartan applies to symptomatic HFrEF patients with LVEF ≤40% across NYHA class II–IV; PARADIGM-HF enrolled predominantly NYHA class II–III patients and demonstrated benefit across these classes; NYHA class II is explicitly included in the recommendation.
Option E: Option E is incorrect; the mortality benefit of sacubitril/valsartan arises from the combined neprilysin inhibition plus AT1 blockade — not from valsartan alone; standalone valsartan does not replicate the ARNI survival benefit; PARADIGM-HF compared sacubitril/valsartan to enalapril, not to valsartan alone; transitioning to valsartan monotherapy would represent a therapeutic downgrade from the current enalapril.